The article discusses how Schwab Corporation is gaining renewed attention due to unusual options trading activity, strong operating updates, and consistent dividends. It highlights the company's earnings momentum, platform scale, client assets, and digital asset expansion plans as key drivers supporting its business narrative and growth.

Benchmark Electronics Inc (BHE) shares rose 3.2% to $86.07, marking a 135.3% increase over the past year. Despite this performance, GuruFocus's GF Value rates BHE as "Significantly Overvalued" at $40.62, with a GF Score of 68/100. Insider activity shows $3.1 million in sales and no purchases over the last three months, signaling potential caution for investors due to the high valuation.

This article focuses solely on the number of shareholders for Princeton Bancorp, Inc. (NASDAQ: BPRN). It provides a high-level overview of the company's stock information, along with links to financial data and news, but does not present the actual number of shareholders. The page appears to be a stub or a placeholder for detailed shareholder data that has not yet been populated.

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) following successful Phase 3 trial results. The drug demonstrated rapid and sustained normalization of calcium metabolism in patients and a favorable safety profile. With a "Buy" rating from analysts and a $101.00 price target, encaleret is poised to be the first approved therapy for ADH1, with potential for expansion into pediatric ADH1 and chronic hypoparathyroidism.

Birkenstock (BIRK) stock dropped 12.9% following its fiscal Q2 results, which reported revenue of €618 million and significant gross margin pressure. The decline in gross margin to 53.9% was mainly due to unfavorable FX translation, incremental U.S. tariffs, and channel mix, despite growth across regions. Investors reacted to the near-term profitability hit, even though the company reaffirmed its full-year targets.

Bionano Genomics, Inc. (BNGO) reported a Q1 loss of $0.76 per share, outperforming the Zacks Consensus Estimate of a $0.81 loss and surpassing year-ago revenues. The company posted revenues of $6.69 million for the quarter ended March 2026, beating estimates by 2.88%. Despite an underperforming stock year-to-date, its earnings outlook is favorable, earning it a Zacks Rank #2 (Buy).

William H. Gates III and Cascade Investment, L.L.C. recently acquired over half a million shares of Republic Services, Inc. (NYSE:RSG) for approximately $100.5 million. These purchases occurred between May 11 and May 13, 2026, with share prices ranging from $197.18 to $203.6701, bringing their collective holdings to over 110 million shares. The waste management company, a 10% owner of which is held by Gates and Cascade, has a market cap of $62.6 billion and a 1.23% dividend yield.

This article provides a comprehensive overview of Coincheck Group N.V.'s (CNCK) SEC filings, including 10-K, 10-Q, and 8-K forms, as tracked by StockTitan. It details recent filings such as KDDI's strategic investment, monthly trading metrics, and insider transactions related to RSU vesting for various executives. The content highlights financial results for fiscal year 2026, where total revenue increased and net loss narrowed, and provides details on company data, rankings, and a list of available tools and articles on the StockTitan platform.

Core Laboratories Inc. held its Annual Meeting of Shareholders on May 12, 2026, where investors re-elected two Class I directors, Harvey Klingensmith and Curtis Anastasio, to terms running until 2029. Shareholders also ratified KPMG LLP as the independent registered public accountant for 2026 and supported the company's executive compensation philosophy. This indicates broad support for Core Laboratories' governance and leadership structure, despite an AI analyst's "Neutral" rating on the stock due to weak technicals but partially offset by improved leverage and solid margins.

Argan Inc (AGX) shares rose 5.7% to $719.92, significantly above its GF Value™ of $139.31, indicating it is approximately 416.8% overvalued. Despite a GF Score™ of 81/100, reflecting strong fundamentals in financial strength, profitability, and growth, its valuation and momentum rankings are low. Insiders have sold $39.1 million worth of shares in the last three months, suggesting a lack of confidence in the current stock price.